E-Therapeutics’ (LON:ETXP)strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and collaborations, potentially in the next 12-24 months, should validate the platform and fund future discovery work and identification of the next wave of lead candidates.
Platform: Approaching a watershed
The network pharmacology platform allows differentiated, potentially disruptive candidates in commercially attractive areas of unmet need to be identified with shorter timelines and reduced cost. Commercialisation will further exploit the productivity of this platform and release value through deals. Three assets are in lead optimisation, with formal preclinical development anticipated to begin in H216. Success in these projects could present significant commercialisation opportunities.
To read the entire report Please click on the pdf File Below